HYALGAN® is administered by intra-articular injection. A treatment cycle consists of 5 injections given at weekly intervals. Some patients may experience benefit with 3 injections given at weekly intervals. This has been noted in studies of patients receiving 3 injections who were followed for 60 days.

Precaution: Do not use HYALGAN® if the package is opened or damaged. Store in the original packaging (protected from light) below 77°F (25°C). DO NOT FREEZE.

Precaution: Strict aseptic administration technique must be followed.

Warning: Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronic acid can precipitate in their presence. Inject subcutaneous lidocaine or similar local anesthetic prior to injection of HYALGAN®.

Precaution: Remove joint effusion fluid, if present, before injection of HYALGAN®. Do not use the same syringe for removing joint effusion fluid and for injecting HYALGAN®. Take care to remove the tip cap of the syringe and needle aseptically. Inject HYALGAN® into the joint through a 20-gauge needle.

Precaution: The vial/syringe is intended for single use. The contents of the vial must be used immediately once the container has been opened. Discard any unused HYALGAN®. Inject the full 2 mL in one knee only. If treatment is bilateral, a separate vial should be used for each knee.¹⁰

HYALGAN® injection video

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.